Horizon Therapeutics Public Limited Company (HZNP) Comparison with companies in other sectors?

Horizon Therapeutics Public Limited Company has a share price of 228.74M. You can analyze Horizon Therapeutics Public Limited Company (HZNP) competitors across different market sectors through stock heatmaps.

What are HZNP's NET and operating margins?

Horizon Therapeutics Public Limited Company (HZNP) operating margin is around 0.17, and net profit margin is approximately 0.14 as of the latest reports.

In what way does HZNP's earnings per share (EPS) trend reflect its financial momentum?

Horizon Therapeutics Public Limited Company (HZNP) EPS is 1.88 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Horizon Therapeutics Public Limited Company is 61.86, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Horizon Therapeutics Public Limited Company?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Horizon Therapeutics Public Limited Company like P/E which is 51.10, P/B which is 5.25, and PEG which is 0.51. Compare them with sector averages to evaluate if the stock is priced fairly.

Horizon Therapeutics Public Limited Company

HZNP•NASDAQ

Healthcare

Drug Manufacturers - General

$116.30

$0.00(0.00%)

Fundamental Analysis of Horizon Therapeutics Public Limited Company (HZNP)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$1.88

P/E Ratio

61.86

ROE

0.11%

Net Margin

0.14%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$26.60B

Shares OutstandingTotal number of shares issued

$228.74M

Book Value/ShareNet worth per share

$22.14

Revenue/ShareAnnual revenue per share

$15.84

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.88

Net MarginNet income as percentage of revenue

14.37%

Operating MarginOperating income as percentage of revenue

17.01%

ROEReturn on shareholders' equity

10.70%

ROAReturn on total assets

5.72%

ROCEReturn on capital employed

7.56%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$4.94

Cash/ShareCash and equivalents per share

$10.39

FCF YieldFree cash flow as percentage of market cap

4.25%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for HZNPFinancial Ratios Analysis details for HZNP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for HZNPSector Benchmarking details for HZNP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Horizon Therapeutics Public Limited Company Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Horizon Therapeutics Public Limited Company. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Horizon Therapeutics Public Limited Company's unique business strengths and challenges.

Key Financial Metrics for Horizon Therapeutics Public Limited Company

For Horizon Therapeutics Public Limited Company, essential financial indicators include EPS 1.88, PE 61.86, and ROE 0.11. These key ratios reveal insights into Horizon Therapeutics Public Limited Company's profitability, valuation, and operational health. Understanding these metrics enables you to compare Horizon Therapeutics Public Limited Company with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Horizon Therapeutics Public Limited Company

Metrics like Net Margin 14.37% and ROA 5.72% shed light on how well Horizon Therapeutics Public Limited Company is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Horizon Therapeutics Public Limited Company can sustain its operations and continue growing in the future.

Valuation and Market Position of Horizon Therapeutics Public Limited Company

Using ratios such as P/B Ratio 5.25 and PEG Ratio 0.51, investors can assess whether Horizon Therapeutics Public Limited Company is appropriately valued based on its financials and growth potential. These figures, combined with Horizon Therapeutics Public Limited Company's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Horizon Therapeutics Public Limited Company

Financial health indicators, such as Debt/Equity Ratio 0.51 and Cash Flow $4.94, provide a snapshot of Horizon Therapeutics Public Limited Company's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Horizon Therapeutics Public Limited Company, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Horizon Therapeutics Public Limited Company

Investing in Horizon Therapeutics Public Limited Company based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Horizon Therapeutics Public Limited Company focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;